Literature DB >> 4917727

Immunosuppression and malignant neoplasms.

T E Starzl, I Penn, C G Halgrimson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1970        PMID： 4917727     DOI： 10.1056/NEJM197010222831714

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  6 in total

1.  Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy.

Authors:  T E Starzl; M A Nalesnik; K A Porter; M Ho; S Iwatsuki; B P Griffith; J T Rosenthal; T R Hakala; B W Shaw; R L Hardesty
Journal:  Lancet       Date:  1984-03-17       Impact factor: 79.321

2.  The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression.

Authors:  M A Nalesnik; R Jaffe; T E Starzl; A J Demetris; K Porter; J A Burnham; L Makowka; M Ho; J Locker
Journal:  Am J Pathol       Date:  1988-10       Impact factor: 4.307

3.  Personal experience with 411 hepatic resections.

Authors:  S Iwatsuki; T E Starzl
Journal:  Ann Surg       Date:  1988-10       Impact factor: 12.969

4.  [Regression of cerebral post-transplantation lymphoma under cyclosporin A reduction].

Authors:  M Fric; A Hartmann; H U Klehr; U Pfeifer; C Herberhold
Journal:  Klin Wochenschr       Date:  1990-12-04

5.  Tissue polypeptide specific antigen for the detection of lymphoproliferative diseases induced by cyclosporin.

Authors:  M Vogl; A Griesmacher; M Grimm; W Klepetko; M M Müller
Journal:  J Clin Pathol       Date:  1995-11       Impact factor: 3.411

Review 6.  CD4 and CD8 T lymphocyte interplay in controlling tumor growth.

Authors:  Dmitrij Ostroumov; Nora Fekete-Drimusz; Michael Saborowski; Florian Kühnel; Norman Woller
Journal:  Cell Mol Life Sci       Date:  2017-10-14       Impact factor: 9.261
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.